Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 7 versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN II 7% vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 7% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for protein synthesis and supports metabolic functions in patients unable to tolerate oral or enteral nutrition.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion; typical adult dose: 0.8-1.5 g amino acids/kg/day (11.4-21.4 mL/kg/day of 7% solution); rate not exceeding 0.1 g amino acids/kg/hour.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
Not applicable; exogenous amino acids are rapidly cleared from plasma with a terminal half-life of 15-20 minutes for individual amino acids.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Renal as amino acids and metabolites; negligible biliary/fecal.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution